FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * CZIRR JAMES C   2. Issuer Name and Ticker or Trading Symbol GALECTIN THERAPEUTICS INC [GALT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Executive Chairman (Last) (First) (Middle) C/O GALECTIN THERAPUETICS, INC., 4960 PEACHTREE INDUSTRIAL BLVD. STE. 240 3. Date of Earliest Transaction (Month/Day/Year) 01/27/2014 (Street) NORCROSS, GA 30071 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 01/27/2014   M   33,333 A $ 3 2,309,519 (1) (2) I By 10X Fund, L.P. Common Stock 01/27/2014   M   50,000 A $ 3 2,359,519 (1) (2) I By 10X Fund, L.P. Common Stock 01/27/2014   M   54,166 A $ 3 2,413,685 (1) (2) I By 10X Fund, L.P. Common Stock 01/27/2014   M   51,666 A $ 3 2,465,351 (1) (2) I By 10X Fund, L.P. Common Stock 01/27/2014   M   54,167 A $ 3 2,519,518 (1) (2) I By 10X Fund, L.P. Common Stock 01/27/2014   M   54,167 A $ 3 2,573,685 (1) (2) I By 10X Fund, L.P. Common Stock 01/27/2014   M   55,834 A $ 3 2,629,519 (1) (2) I By 10X Fund, L.P. Common Stock 01/27/2014   M   51,667 A $ 3 2,681,186 (1) (2) I By 10X Fund, L.P. Common Stock 01/27/2014   M   95,000 A $ 3 2,776,186 (1) (2) I By 10X Fund, L.P. Common Stock               179,232 I By Trust Common Stock               844,450 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Class A-2 Warrant (Right to Buy)

$ 3

01/27/2014

M

33,333

06/30/2009

06/30/2019

Common Stock

33,333

$ 0 (3)

0

I

By 10X Fund, L.P.

Class A-2 Warrant (Right to Buy)

$ 3

01/27/2014

M

50,000

08/12/2009

08/12/2019

Common Stock

50,000

$ 0 (4)

0

I

By 10X Fund, L.P.

Class A-2 Warrant (Right to Buy)

$ 3

01/27/2014

M

54,166

09/30/2009

09/30/2019

Common Stock

54,166

$ 0 (5)

0

I

By 10X Fund, L.P.

Class A-2 Warrant (Right to Buy)

$ 3

01/27/2014

M

51,666

11/03/2009

11/03/2019

Common Stock

51,666

$ 0 (6)

0

I

By 10X Fund, L.P.

Class A-2 Warrant (Right to Buy)

$ 3

01/27/2014

M

54,167

12/08/2009

12/08/2019

Common Stock

54,167

$ 0 (7)

0

I

By 10X Fund, L.P.

Class A-2 Warrant (Right to Buy)

$ 3

01/27/2014

M

54,167

01/29/2010

01/29/2020

Common Stock

54,167

$ 0 (8)

0

I

By 10X Fund, L.P.

Class A-2 Warrant (Right to Buy)

$ 3

01/27/2014

M

55,834

03/08/2010

03/08/2020

Common Stock

55,834

$ 0 (9)

0

I

By 10X Fund, L.P.

Class A-2 Warrant (Right to Buy)

$ 3

01/27/2014

M

51,667

04/30/2010

04/30/2020

Common Stock

51,667

$ 0 (10)

0

I

By 10X Fund, L.P.

Class A-2 Warrant (Right to Buy)

$ 3

01/27/2014

M

95,000

05/10/2010

05/10/2020

Common Stock

95,000

$ 0 (11)

0

I

By 10X Fund, L.P.

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
CZIRR JAMES C C/O GALECTIN THERAPUETICS, INC. 4960 PEACHTREE INDUSTRIAL BLVD. STE. 240 NORCROSS, GA 30071	X		Executive Chairman

Signatures

/s/ James C. Czirr		01/28/2014
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Amount reflects the Issuer's March 23, 2012 one-for-six reverse stock split. This filing amends all previous filings since the reverse stock split to reflect post-split beneficial holdings.
(2)	Reporting person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
(3)	On June 30, 2009, 10X Fund, L.P. purchased (a) 250,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 83,333 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 83,333 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 333,333 shares of Common Stock for $3.00 per share, for aggregate consideration of $500,000.
(4)	On August 12, 2009, 10X Fund, L.P. purchased (a) 150,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 50,000 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 50,000 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 200,000 shares of Common Stock for $3.00 per share, for aggregate consideration of $300,000.
(5)	On September 30, 2009, 10X Fund, L.P. purchased (a) 162,500 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 54,166 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 54,166 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 216,666 shares of Common Stock for $3.00 per share, for aggregate consideration of $325,000.
(6)	On November 3, 2009, 10X Fund, L.P. purchased (a) 155,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 51,666 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 51,666 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 206,667 shares of Common Stock for $3.00 per share, for aggregate consideration of $310,000.
(7)	On December 8, 2009, 10X Fund, L.P. purchased (a) 162,500 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 54,167 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 54,167 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 216,667 shares of Common Stock for $3.00 per share, for aggregate consideration of $325,000.
(8)	On January 29, 2010, 10X Fund, L.P. purchased (a) 162,500 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 54,167 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 54,167 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 216,667 shares of Common Stock for $3.00 per share, for aggregate consideration of $325,000.
(9)	On March 8, 2010, 10X Fund, L.P. purchased (a) 167,500 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 55,834 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 55,834 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 223,333 shares of Common Stock for $3.00 per share, for aggregate consideration of $335,000.
(10)	On April 30, 2010, 10X Fund, L.P. purchased (a) 155,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 51,667 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 51,667 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 206,667 shares of Common Stock for $3.00 per share, for aggregate consideration of $310,000.
(11)	On May 10, 2010, 10X Fund, L.P. purchased (a) 285,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 95,000 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 95,000 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 380,000 shares of Common Stock for $3.00 per share, for aggregate consideration of $570,000.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.